Effectiveness and safety of apixaban, dabigatran and warfarin compared to rivaroxaban in non-valvular atrial fibrillation; a Norwegian nationwide cohort study

被引：0
|
作者：
Rutherford, O. -C. W. [1 ]
Jonasson, C. J. [2 ]
Ghanima, W. G. [3 ]
Halvorsen, S. H. [4 ]
机构：
[1] Ostfold Hosp Trust, Dept Cardiol, Sarpsborg, Norway
[2] Norwegian Univ Sci & Technol, HUNT Res Ctr, Fac Med, Trondheim, Norway
[3] Ostfold Hosp Trust, Dept Haematol, Sarpsborg, Norway
[4] Oslo Univ Hosp, Dept Cardiol, Oslo, Norway
来源：
EUROPEAN HEART JOURNAL | 2019年 / 40卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3051
引用
收藏
页码：1846 / 1846
页数：1
相关论文
共 50 条
  • [1] Comparative effectiveness of warfarin, dabigatran, rivaroxaban and apixaban in non-valvular atrial fibrillation: A nationwide pharmacoepidemiological study
    Kjerpeseth, Lars J.
    Selmer, Randi
    Ariansen, Inger
    Karlstad, Oystein
    Ellekjaer, Hanne
    Skovlund, Eva
    [J]. PLOS ONE, 2019, 14 (08):
  • [2] EFFECTIVENESS AND SAFETY OF APIXABAN, DABIGATRAN, AND RIVAROXABAN COMPARED TO WARFARIN AMONG NON-VALVULAR ATRIAL FIBRILLATION PATIENTS IN THE US MEDICARE POPULATION
    Amin, Alpesh
    Keshishian, Allison
    Trocio, Jeffrey
    Le, Hannah
    Dina, Oluwaseyi
    Zhang, Qisu
    Baser, Onur
    Vo, Lien
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2017, 69 (11) : 316 - 316
  • [3] Comparative effectiveness and safety of apixaban, dabigatran, and rivaroxaban in patients with non-valvular atrial fibrillation
    Andersson, Niklas W.
    Svanstrom, Henrik
    Lund, Marie
    Pasternak, Bjorn
    Melbye, Mads
    [J]. INTERNATIONAL JOURNAL OF CARDIOLOGY, 2018, 268 : 113 - 119
  • [4] Comparison of dabigatran, rivaroxaban, and apixaban for effectiveness and safety in atrial fibrillation: a nationwide cohort study
    Rutherford, Ole-Christian W.
    Jonasson, Christian
    Ghanima, Waleed
    Soderdahl, Fabian
    Halvorsen, Sigrun
    [J]. EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY, 2020, 6 (02) : 75 - 85
  • [5] The risk of acute kidney injury in Asians treated with apixaban, rivaroxaban, dabigatran, or warfarin for non-valvular atrial fibrillation: A nationwide cohort study in Taiwan
    Chan, Yi-Hsin
    Yeh, Yung-Hsin
    Hsieh, Mei-Yun
    Chang, Chia-Yu
    Tu, Hui-Tzu
    Chang, Shang-Hung
    See, Lai-Chu
    Kuo, Chang-Fu
    Kuo, Chi-Tai
    [J]. INTERNATIONAL JOURNAL OF CARDIOLOGY, 2018, 265 : 83 - 89
  • [6] Comparison of warfarin, dabigatran, rivaroxaban and apixaban for effectiveness and safety among elderly patients with atrial fibrillation: a nationwide cohort study
    Rutherford, O. C. W.
    Jonasson, C.
    Ghanima, W.
    Soderdahl, F.
    Halvorsen, S.
    [J]. EUROPEAN HEART JOURNAL, 2020, 41 : 662 - 662
  • [7] Comparative Effectiveness of Dabigatran and Rivaroxaban versus Warfarin in Patients With Non-Valvular Atrial Fibrillation
    Bengtson, Lindsay
    Chen, Lin
    MacLehose, Richard
    Lutsey, Pamela
    Alonso, Alvaro
    [J]. CIRCULATION, 2014, 130
  • [8] Comparative effectiveness of dabigatran and rivaroxaban versus warfarin for the treatment of non-valvular atrial fibrillation
    Bengtson, Lindsay G. S.
    Lutsey, Pamela L.
    Chen, Lin Y.
    MacLehose, Richard F.
    Alonso, Alvaro
    [J]. JOURNAL OF CARDIOLOGY, 2017, 69 (5-6) : 868 - 876
  • [9] Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin for Stroke Prevention in Non-Valvular Atrial Fibrillation: A Cost-Effectiveness Analysis
    Rognoni, Carla
    Marchetti, Monia
    Quaglini, Silvana
    Liberato, Nicola Lucio
    [J]. CLINICAL DRUG INVESTIGATION, 2014, 34 (01) : 9 - 17
  • [10] Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin for Stroke Prevention in Non-Valvular Atrial Fibrillation: A Cost-Effectiveness Analysis
    Carla Rognoni
    Monia Marchetti
    Silvana Quaglini
    Nicola Lucio Liberato
    [J]. Clinical Drug Investigation, 2014, 34 : 9 - 17
12345